{
    "id": "52962989",
    "text": "Eflapegrastim (HM-10460A) is a long acting G-CSF analog developed by Hanmi Pharmaceutical and licensed to Spectrum Pharmaceuticals. It was developed for the treatment of chemotherapy-induced neutropenia. It is in phase III clinical trials comparing the efficacy to that of pegfilgrastim in patients with breast cancer. == References == Category:Experimental cancer drugs ",
    "title": "Eflapegrastim"
}